Huntington Ingalls Industries, Inc.
—- Market cap
- $11.08B
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HII stock price at discount vs AMGN $281.20 current versus $409.73 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Implied fair value · at HII's multiple
Snapshot Sep 11, 2026, 2:09 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 79% equity / 21% debt · EV / Revenue 6.81x · EV proxy / EBITDA proxy 17.57x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HUNTINGTON INGALLS INDUSTRIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
GENERAL DYNAMICS CORP
HII vs GD
LOCKHEED MARTIN CORP
HII vs LMT
NORTHROP GRUMMAN CORP /DE/
HII vs NOC
TEXTRON INC
HII vs TXT
Howmet Aerospace Inc.
HII vs HWM
AXON ENTERPRISE, INC.
HII vs AXON
REGENERON PHARMACEUTICALS, INC.
HII vs REGN
BIOGEN INC.
HII vs BIIB
VERTEX PHARMACEUTICALS INC / MA
HII vs VRTX
Gilead Sciences, Inc.
HII vs GILD
Moderna, Inc.
HII vs MRNA
Eli Lilly and Company
HII vs LLY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HII can sustain higher margins and re-rate closer to the P/E-derived value despite its much weaker profitability than AMGN, then the stock can be held or added; otherwise, the current price looks hard to justify because the DCF range and operating metrics both point to limited fundamental support.
The P/E-based implied price of $416.56 suggests 27.6% upside from HII’s current $326.45 price, but that uplift is hard to reconcile with the rest of the valuation set. HII also sits above the top end of the DCF range and above the historical band midpoint, indicating the market is already pricing in a relatively full multiple.
Supporting Metrics